ight no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes pmc-license-ref CC BY document-id-old-9 bc4c00144 document-id-new-14 bc4c00144 ccc-price 1 Introduction The development of theranostic fluorescence imaging agents and radiopharmaceuticals is an important trend in cancer diagnosis and treatment, 1 and selecting a specific cancer-related protein target is essential for success.
← all excerpts
High-Affinity NIR-Fluorescent Inhibitors for Tumor Imaging via Carbonic Anhydrase IX.
1
—
—